



RON DESANTIS
GOVERNOR

SHEVAUN HARRIS
SECRETARY

Pharmaceutical & Therapeutics Committee

Florida Agency for Health Care Administration

Zoom Webinar Only, Friday, June 27, 2025 – 8:30 a.m. Eastern Time (US and Canada)

Join from PC, Mac, iPad, or Android:

<https://primetherapeutics.zoom.us/j/82580569803>

Phone one-tap:

+13462487799,82580569803# US (Houston)

+13602095623,82580569803# US

Join via audio:

+1 346 248 7799 US (Houston)

+1 360 209 5623 US

+1 386 347 5053 US

+1 507 473 4847 US

+1 564 217 2000 US

+1 646 558 8656 US (New York)

+1 646 931 3860 US

+1 669 444 9171 US

+1 669 900 9128 US (San Jose)

+1 689 278 1000 US

+1 719 359 4580 US

+1 253 205 0468 US

+1 253 215 8782 US (Tacoma)

+1 301 715 8592 US (Washington DC)

+1 305 224 1968 US

+1 309 205 3325 US

+1 312 626 6799 US (Chicago)

Webinar ID: 825 8056 9803

International numbers available: <https://primetherapeutics.zoom.us/j/82580569803>

Join from an H.323/SIP room system:

H.323:

144.195.19.161 (US West)

206.247.11.121 (US East) Meeting ID: 825 8056 9803

SIP: [82580569803@zoomcrc.com](https://primetherapeutics.zoom.us/j/82580569803)



Agenda

Call to Order

Jennifer Lalani, RPh, CPh, Florida Medicaid P&T Committee Chair

Opening Remarks and Introductions

Francisco Burgin, PharmD, Pharmacy Policy Administrator, AHCA

Notice of Disclosure and Sunshine Law

Marquetta Howard-Chambers, Medicaid Policy, AHCA

Review of Rebate Process for Open and Executive Sessions

Kara Delaney, PharmD, Prime Therapeutics

Public Testimony

Jennifer Lalani, RPh, CPh, Chair

Open Session Ends, Executive Session Commences

Kara Delaney, PharmD, Prime Therapeutics

Open Session Resumes

Kara Delaney, PharmD, Prime Therapeutics

Approval of P&T Minutes from March 14, 2025

Jennifer Lalani, RPh, CPh, Chair

Therapeutic Class Reviews

Jennifer Lalani, RPh, CPh, Chair

Open Discussion

Review of DUR Activity

Makala Burkhart, PharmD, Prime Therapeutics

Adjourn



RON DESANTIS
GOVERNOR

SHEVAUN HARRIS
SECRETARY

Therapeutic Class Reviews

- ALZHEIMER'S AGENTS
- ANTIPARKINSON'S AGENTS
- ANTIPSYCHOTICS
- ERYTHROPOIESIS STIMULATING PROTEINS
- GI MOTILITY, CHRONIC
- GROWTH HORMONE
- HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS
- HYPOGLYCEMICS, INSULIN AND RELATED AGENTS
- HYPOGLYCEMICS, SGLT2
- IMMUNE GLOBULINS
- IMMUNOMODULATORS, ASTHMA
- IMMUNOMODULATORS, ATOPIC DERMATITIS
- IMMUNOSUPPRESSIVES, ORAL
- LIPOTROPICS, OTHER
- MOVEMENT DISORDERS
- MULTIPLE SCLEROSIS AGENTS
- OPIATE DEPENDENCE TREATMENTS
- PAH AGENTS, ORAL AND INHALED
- PITUITARY SUPPRESSIVE AGENTS, LHRH
- POTASSIUM BINDERS
- STIMULANTS AND RELATED AGENTS

Mass Review Classes

- ACNE AGENTS, ORAL
- ANALGESICS, NON-SAL/BARBITURATE
- ANALGESICS, NON-SAL/BARBITURATE/XANTHINE
- ANALGESICS, SAL/BARBITURATE/XANTHINE
- ANALGESICS, SALICYLATES
- ANTI-ALCOHOLIC PREPARATIONS
- ANTIFUNGALS, VAGINAL
- ANTIHYPERTENSIVES, SYMPATHOLYTICS
- ANTIHYPERTENSIVES, VASODILATORS
- ANTIPSORIATICS, ORAL
- ANTITHYROID PREPARATIONS
- ANTI-ULCER PROTECTANTS
- ANXIOLYTICS
- ENZYME INHIBITORS, SYSTEMIC
- ESTROGEN AGENTS, COMBINATION
- ESTROGEN AGENTS, INJECTABLE
- ESTROGEN AGENTS, ORAL/TRANSDERM
- FOLIC ACID PREPARATIONS
- GLUCOCORTICIDS, INJECTABLE
- GLUCOCORTICIDS, ORAL
- HISTAMINE II RECEPTOR BLOCKER
- HYPOGLYCEMICS, METFORMINS
- HYPOGLYCEMICS, SULFONYLUREAS
- LITHIUM AGENTS
- MUCOLYTICS
- ONCOLOGY, INJECTABLE
- PAH AGENTS, INJECTABLE
- PRENATAL VITAMINS
- ROSACEA AGENTS, TOPICAL
- UREA CYCLE DISORDERS, ORAL



Single Product Reviews

- ANTIDEPRESSANTS, OTHER
 - RALDESY SOLUTION (ORAL)
- ANTIMIGRAINE AGENTS, OTHER
 - SYMBRAVO TABLET (ORAL)
- MISCELLANEOUS
 - JOURNAVX TABLET (ORAL)